NASDAQ:ACTU Actuate Therapeutics (ACTU) Stock Price, News & Analysis $7.28 +0.03 (+0.34%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Actuate Therapeutics Stock (NASDAQ:ACTU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Actuate Therapeutics alerts:Sign Up Key Stats Today's Range$6.77▼$7.3250-Day Range$5.66▼$11.3652-Week Range$5.47▼$11.99Volume46,101 shsAverage Volume68,192 shsMarket Capitalization$148.93 millionP/E RatioN/ADividend YieldN/APrice Target$20.50Consensus RatingBuy Company Overview Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas. Read More Actuate Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreACTU MarketRank™: Actuate Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 589th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingActuate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageActuate Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Actuate Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioActuate Therapeutics has a P/B Ratio of 727.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ACTU. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldActuate Therapeutics does not currently pay a dividend.Dividend GrowthActuate Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ACTU. News and Social Media1.0 / 5News Sentiment-0.24 News SentimentActuate Therapeutics has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Actuate Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ACTU on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Actuate Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,499,988.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders69.34% of the stock of Actuate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Actuate Therapeutics' insider trading history. Receive ACTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACTU Stock News HeadlinesActuate Therapeutics, Inc. (NASDAQ:ACTU) Director Equity Cof Lp Bios Buys 71,428 SharesJuly 1, 2025 | insidertrades.comCraig-Hallum Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)5 hours ago | theglobeandmail.comIs America’s Everything Bubble About to Burst?On July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushing America’s debt-to-GDP ratio to 175%. Top investors are warning of an epic bubble bursting soon. A free guide reveals how to shield your 401(k), savings, and portfolio before the collapse.August 1 at 2:00 AM | American Alternative (Ad)Actuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B MeetingJuly 30 at 8:17 AM | seekingalpha.comActuate Therapeutics registers 1.33M shares for resale by investorsJuly 25, 2025 | msn.comActuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric SarcomasJuly 17, 2025 | globenewswire.comActuate Therapeutics, Inc.June 30, 2025 | cnn.comActuate Therapeutics Reports Promising Survival Outcomes in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - NasdaqJune 26, 2025 | nasdaq.comSee More Headlines ACTU Stock Analysis - Frequently Asked Questions How have ACTU shares performed this year? Actuate Therapeutics' stock was trading at $7.96 on January 1st, 2025. Since then, ACTU stock has decreased by 8.6% and is now trading at $7.2750. How were Actuate Therapeutics' earnings last quarter? Actuate Therapeutics, Inc. (NASDAQ:ACTU) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.06. When did Actuate Therapeutics IPO? Actuate Therapeutics (ACTU) raised $27 million in an IPO on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners served as the underwriter for the IPO and Newbridge Securities Corp. was co-manager. Who are Actuate Therapeutics' major shareholders? Top institutional shareholders of Actuate Therapeutics include Gleason Group Inc. (0.10%). Insiders that own company stock include Todd S Thomson, Leslie W Kreis, Equity Cof Lp Bios and Aaron GL Fletcher. View institutional ownership trends. How do I buy shares of Actuate Therapeutics? Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Actuate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN). Company Calendar Last Earnings5/15/2025Today8/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACTU Previous SymbolNASDAQ:ACTU CIK1652935 WebN/A Phone(847) 986-4190FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Actuate Therapeutics$20.50 High Price Target$21.00 Low Price Target$20.00 Potential Upside/Downside+181.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.28 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-339.73% Debt Debt-to-Equity RatioN/A Current Ratio0.46 Quick Ratio0.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book727.50Miscellaneous Outstanding Shares20,471,000Free Float6,276,000Market Cap$148.93 million OptionableN/A BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ACTU) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | SponsoredMusk's Big Prediction for 2025Elon Musk just made a bold prediction about 2025—and it could upend the entire tech sector. If he’s right, ...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.